GART Polyclonal Antibody, FITC Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-13288R-FITC-100uL |
| Product Name | GART Polyclonal Antibody, FITC Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Chicken |
| Specifications | |
| Conjugation | FITC |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human GART |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 2618 |
| Swiss Prot | P22102 |
| Subcellular location | Cytoplasm |
| Synonyms | 5'-phosphoribosylglycinamide transformylase; AIR synthase; AIRS; GAR transformylase; GARS; GART; GART; GARTF; Glycinamide ribonucleotide synthetase; MGC47764; PAIS; PGFT; Phosphoribosyl-aminoimidazole synthetase; Phosphoribosylglycinamide formyltransferase; Phosphoribosylglycinamide formyltransferase phosphoribosylglycinamide synthetase phosphoribosylaminoimidazole synthetase; Phosphoribosylglycinamide formyltransferase, EC 2.1.2.29; Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase; Phosphoribosylglycinamide synthetase; PRGS; PUR2_HUMAN; Trifunctional purine biosynthetic protein adenosine 3. |
| Background | Purines are critical for energy metabolism, cell signaling and cell reproduction and also function as precursors for coenzymes, energy transfer molecules, regulatory factors and proteins involved in RNA and DNA synthesis. GART (GAR transformylase), also referred to as AIRS, GARS, PAIS, PGFT, PRGS or GARTF, is 1,010 amino acids in length and is a key folate-dependent trifunctional enzyme with phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase and AICAR (phosphoribosylaminoimidazole synthetase) activity required for de novo purine biosynthesis. Cancer cells require considerable amounts of purines to sustain their accelerated growth and GART is, therefore, a target for cancer chemotherapy. GART is highly conserved in vertebrates. Two isoforms of GART are expressed due to alternative splicing events. |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is GART Polyclonal Antibody, FITC Conjugated (bs-13288R-FITC) validated for, and at what dilution?
bs-13288R-FITC is validated for IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should bs-13288R-FITC be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise GART Polyclonal Antibody, FITC Conjugated (bs-13288R-FITC)?
KLH conjugated synthetic peptide derived from human GART
What are the excitation and emission wavelengths of the FITC conjugate (bs-13288R-FITC)?
FITC on bs-13288R-FITC: excitation / emission 494nm/518nm.